Phase I results for rectally administered microbicide gel formulated with IQP-0528 March 12, 2020 No Comments
Broadly neutralizing antibody plus latency reversing treatment evaluated in HIV trial March 11, 2020 No Comments
Encouraging 48-week data from phase III ATLAS-2M study of long-acting HIV regimen March 10, 2020 No Comments
RSS